

P&T Motion History Second Generation Antidepressants

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
SSRI: citalopram escitalopram fluoxetine fluvoxamine paroxetine sertraline vilazodone vortioxetine SNRI/SSNRI: desvenlafaxine duloxetine levomilnacipran venlafaxine OTHER: bupropion mirtazapine nefazodone <i>trazadone</i>	After considering the evidence of safety, efficacy and special populations for their FDA approved indications, I move that bupropion, citalopram, duloxetine, escitalopram, fluoxetine, sertraline, fluvoxamine, levomilnacipran, mirtazapine, paroxetine, desvenlafaxine, venlafaxine, vortioxetine and vilazodone are safe and efficacious for their approved indications. The Washington Preferred Drug List must include as preferred at least two SSRIs one of which must have an indication for pediatric and adolescent use, at least one SNRI or SSNRI, mirtazapine, and bupropion. The second generation antidepressants cannot be subject to therapeutic interchange in the Washington preferred drug list. Nefazodone is also efficacious for its approved indications but does have a higher risk of hepatic toxicity and so should not be a preferred drug on the PDL. Motion: Schwilke 2 nd : Flatebo	October 19, 2022	Yes Buccola Schwilke	Yes Buccola Chawla	Passed unanimous

Bold = new this update

Grey italic = not part of PDL program

10/20/2022